KCM
SNDX icon

Kynam Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Kynam Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-400,000
Closed -$5.81M – 32
2023
Q3 		$5.81M Buy
+400,000
New +$7.57M 0.95% 19

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kynam Capital Management's SNDX Position: Q1 2026 in Review

Kynam Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q1 2026 at 8,050,959 shares worth $188M. The position accounts for 11.6% of the portfolio, ranked #1.

Kynam Capital Management first reported a position in SNDX in Q4 2021 and has held it in 18 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Kynam Capital Management held 8,050,959 shares of Syndax Pharmaceuticals worth $188M as of Q1 2026.
  • Kynam Capital Management left its Syndax Pharmaceuticals share count unchanged in Q1 2026.
  • Syndax Pharmaceuticals made up 11.6% of Kynam Capital Management's portfolio in Q1 2026, its #1 holding.
  • Kynam Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.